1 May 2011Big PharmaClaire Baldock

Windows of opportunity and closing doors at the EPO

The European Patent Office’s (EPO) approach to granting patents and how it goes about doing this have a large influence on the health of the pharmaceutical sector. The competitiveness and worth of innovative pharmaceuticals are linked to the strength of its patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

Big Pharma

INTA: ‘New normal’ for in-house counsel as budgets fall

16 March 2026 Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.

More features

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

IndiaMart v CDSCO: A test of intermediary liability

Novartis bets $2bn on biologics as Xolair patents fade

WIPR debuts Global In-House Elite 2026

Windows of opportunity and closing doors at the EPO

More on this story

Editor's picks

Editor's picks

More features